Strikes the Balance between Efficacy and toxicity
|Generic Name||Strength||Type||Packing||Pack Size|
|Capecitabine||500 mg||Tablet||6's Strip||3*6 Tablets|
|Capecitabine||150 mg||Tablet||6's Strip||3*6 Tablets|
Capecitabine is an Antineoplastic & Antimetabolite chemotherapy agent.
What Capecitabine is used for ?....Capecitabine is used for the treatement of Anthracycline resistant cases of Metastatic Breast Cancer.
Dose Window.... 1250mg/m2 PO BID for 2 weeks q21 days.
1250mg/m2 BID for 2 weeks q21 days plus Docetaxel 75mg/m2 1 Hour IV
Note : If a drug has been approved for one use Doctors some time elect to use the same drug for some other problems if they believe it might be helpful.
- C-Bine (capecitabine) is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. Capecitabine was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Physicians should consider results of combination chemotherapy trials, which have shown improvement in DFS and OS,
- C-Bine (capecitabine) is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with capecitabine monotherapy. Use of capecitabine instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage.
- C-Bine(capecitabine) in combination with docetaxel is indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
- Capecitabine monotherapy is also indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated (e.g., patients who have received cumulative doses of 400 mg/m² of doxorubicin or doxorubicin equivalents). Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen.